About Numenos AI

NUMENOS utilizes AI-driven Foundation Models to enhance drug development by integrating and analyzing real-world data and clinical trial data, enabling biomarker-driven target discovery and patient stratification. This approach significantly reduces trial sizes by 50-70% and increases trial significance by an average of 10 times, addressing the inefficiencies of traditional drug development methods.

```xml <problem> Traditional drug development methods face inefficiencies due to limited sample sizes and the high dimensionality of clinical trial data, hindering the applicability of machine learning and artificial intelligence, and resulting in lost potential for identifying effective treatments. Existing approaches often struggle to fully leverage the wealth of information contained within clinical trial data to guide decision-making and patient stratification. </problem> <solution> NUMENOS offers an AI-driven platform, CURE, that enhances drug development by integrating and analyzing real-world data (RWD) and Phase I-IV clinical trial data. The CURE platform leverages a proprietary, integrated, and interpretable foundation model with over 100 million parameters to unravel causal and predictive biomarkers and targets. By revealing molecular fingerprints of patients most likely to benefit from a given therapy and disease mechanisms, CURE enables biomarker-driven target discovery, patient stratification, and reverse translation. This approach guides data-driven decision-making, potentially leading to faster trials, drug differentiation, and the prioritization of assets relevant to multiple indications. </solution> <features> - Integration and analysis of RWD and Phase I-IV clinical data - Proprietary, integrated, and interpretable foundation model with over 100 million parameters - Identification of causal and predictive biomarkers and targets - Unraveling of disease progression mechanisms and biological mechanisms behind drug benefit - Patient stratification based on molecular fingerprints - Biomarker-driven reverse and forward translation for clinically driven target discovery </features> <target_audience> The primary audience includes pharmaceutical companies, biotech firms, and research institutions involved in drug development, clinical trials, and biomarker discovery. </target_audience> ```

What does Numenos AI do?

Where is Numenos AI located?

Numenos AI is based in Tel Aviv, Israel.

When was Numenos AI founded?

Numenos AI was founded in 2023.

Location

Tel Aviv, Israel

Founded

2023

Employees

8 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Numenos AI

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

numenos.ai 50+

Founded 2023 – Tel Aviv, Israel

Funding

No funding information available.

Team (5+)

No team information available.

Company Description

Problem

Traditional drug development methods face inefficiencies due to limited sample sizes and the high dimensionality of clinical trial data, hindering the applicability of machine learning and artificial intelligence, and resulting in lost potential for identifying effective treatments. Existing approaches often struggle to fully leverage the wealth of information contained within clinical trial data to guide decision-making and patient stratification.

Solution

NUMENOS offers an AI-driven platform, CURE, that enhances drug development by integrating and analyzing real-world data (RWD) and Phase I-IV clinical trial data. The CURE platform leverages a proprietary, integrated, and interpretable foundation model with over 100 million parameters to unravel causal and predictive biomarkers and targets. By revealing molecular fingerprints of patients most likely to benefit from a given therapy and disease mechanisms, CURE enables biomarker-driven target discovery, patient stratification, and reverse translation. This approach guides data-driven decision-making, potentially leading to faster trials, drug differentiation, and the prioritization of assets relevant to multiple indications.

Features

Integration and analysis of RWD and Phase I-IV clinical data

Proprietary, integrated, and interpretable foundation model with over 100 million parameters

Identification of causal and predictive biomarkers and targets

Unraveling of disease progression mechanisms and biological mechanisms behind drug benefit

Patient stratification based on molecular fingerprints

Biomarker-driven reverse and forward translation for clinically driven target discovery

Target Audience

The primary audience includes pharmaceutical companies, biotech firms, and research institutions involved in drug development, clinical trials, and biomarker discovery.